| Methods |
Allocation: randomised.
Blindness: double, no further detail.
Duration: six weeks.
Setting: not reported. |
| Participants |
Diagnosis: schizophrenia (CCMD‐2‐R).
N=41.
Age: mean 28.
Sex: not reported.
History: naive antipsychotics; mean duration of illness ˜ 13 yrs. |
| Interventions |
1. Clozapine: dose average 188 mg/day. N=20.
2. Clopenthixol: dose average 36 mg/day. N=21. |
| Outcomes |
Mental state: BPRS.
Adverse effects: TESS, SAS, Myotonia, Akathisia, Tachycardia, Blood cell counting, Salivation. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Randomised ‐ no details |
| Allocation concealment? |
Unclear risk |
No details |
| Blinding?
All outcomes |
Unclear risk |
Two raters did not conduct treatment |
| Incomplete outcome data addressed?
All outcomes |
Unclear risk |
No details |
| Free of selective reporting? |
Unclear risk |
No details |
| Free of other bias? |
Unclear risk |
No details |
